|
US7037922B1
(en)
*
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
AU4038000A
(en)
|
1999-03-29 |
2000-10-16 |
Neurogen Corporation |
4-substituted quinoline derivatives as gaba receptor ligands
|
|
JP2003502314A
(ja)
|
1999-06-14 |
2003-01-21 |
イーライ・リリー・アンド・カンパニー |
化合物
|
|
US6794393B1
(en)
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
CA2387351C
(en)
|
1999-10-19 |
2009-09-08 |
Merck & Co., Inc. |
Indole derivatives as tyrosine kinase inhibitors
|
|
US6420382B2
(en)
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
ATE303998T1
(de)
|
2000-10-17 |
2005-09-15 |
Merck & Co Inc |
Oral aktive salze mit tyrosinkinaseaktivität
|
|
GB0028964D0
(en)
*
|
2000-11-28 |
2001-01-10 |
Smithkline Beecham Spa |
Novel compounds
|
|
US7169788B2
(en)
|
2001-10-30 |
2007-01-30 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2004002484A1
(ja)
*
|
2002-06-26 |
2004-01-08 |
Kyowa Hakko Kogyo Co., Ltd. |
ホスホジエステラーゼ阻害剤
|
|
EP1911763B1
(en)
|
2003-01-28 |
2010-08-11 |
Ironwood Pharmaceuticals, Inc. |
Compositions for the treatment of gastrointestinal disorders
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
RU2229475C1
(ru)
*
|
2003-03-06 |
2004-05-27 |
ООО "Исследовательский институт химического разнообразия |
6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
|
|
TW200804288A
(en)
|
2005-12-12 |
2008-01-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
MX354786B
(es)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
|
|
US20090118135A1
(en)
*
|
2007-06-08 |
2009-05-07 |
The Burnham Institute |
Methods and compounds for regulating apoptosis
|
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
MX381407B
(es)
|
2008-12-31 |
2025-03-12 |
Ardelyx Inc |
Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
MX366293B
(es)
|
2012-08-21 |
2019-07-04 |
Ardelyx Inc |
Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
AU2014235215A1
(en)
|
2013-03-15 |
2015-10-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
HRP20191000T1
(hr)
|
2013-04-12 |
2019-09-20 |
Ardelyx, Inc. |
Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
|
|
WO2014170648A1
(en)
|
2013-04-19 |
2014-10-23 |
Astrazeneca Ab |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
|
EP3166928B1
(en)
*
|
2014-07-08 |
2019-04-03 |
Dow AgroSciences LLC |
Process for the preparation of 3-hydroxypicolinic acids
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
MX395405B
(es)
|
2017-01-09 |
2025-03-25 |
Ardelyx Inc |
Compuestos útiles para tratar trastornos del tracto gastrointestinal.
|
|
MX2019008171A
(es)
|
2017-01-09 |
2020-02-05 |
Ardelyx Inc |
Inhibidores del antiporte mediado por nhe.
|
|
CN113194948A
(zh)
*
|
2018-11-15 |
2021-07-30 |
国立大学法人九州大学 |
Il-31介导性疾病的预防或治疗剂及医药组合物
|